Full text is available at the source.
Abstract
Four studies in 2024 examined chronic kidney disease progression and cardiovascular events related to semaglutide or sodium-glucose cotransporter-2 inhibitors.
- Studies assessed the relationship between chronic kidney disease and cardiovascular issues concerning specific medications.
- Mineralocorticoid receptor agonists may help manage heart failure in patients with chronic kidney disease.
- Avenciguat could improve albuminuria levels in chronic kidney disease patients.
- Oral phosphate binders are associated with addressing the risk of fractures in chronic kidney disease.
- Inorganic nitrate was shown to reduce the risk of contrast-induced nephropathy.
- A trial indicated that cefepime-taniborbactam may be beneficial for complicated urinary tract infections.
Simplified